DNMT1
ENSG00000130816
Target class
Epigenetic regulator
Chromosome
19
Approved drugs
2
Clinical candidates (approved and in development)
2
- Approved drugs
- 2
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- Yes
- Target name
- DNMT1
- Gene name
- DNA methyltransferase 1
- Gene symbol
- DNMT1
- Previous gene symbols
- DNMT
- Protein name
- DNA (cytosine-5)-methyltransferase 1 (Dnmt1) (EC 2.1.1.37) (CXXC-type zinc finger protein 9) (DNA methyltransferase HsaI) (DNA MTase HsaI) (M.HsaI) (MCMT)
- MCMT
- CXXC9
- Gene biotype
- Protein coding
- Gene family
- Zinc fingers CXXC-type|7BS C5-cytosine DNA/RNA methyltransferases|DNA/RNA methyltransferases
- Target class
- Epigenetic regulator
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 83.96
- Tissue specificity (Gini)
- 0.368
- Tissue specificity (tau)
- 0.772
- KEGG gene identifiers
- hsa:1786
- Protein interaction confidence
- 0.870206
- Protein interaction partners
- 126
- R-HSA-212300
- R-HSA-427413
- R-HSA-4655427
- R-HSA-5334118
- R-HSA-9701898
- R-HSA-9710421
- R-HSA-9725371
- End position
- 10231286
- Start position
- 10133342
- Chromosome
- 19
- Strand
- Reverse
- Nucleus . Chromosome . Note=Associates with replication foci during S-phase: recruited to hemimethylated DNA sites via its RFTS domain, which specifically recognizes and binds histone H3 ubiquitinated at 'Lys-14', 'Lys-18' and 'Lys-23' (H3K14ub, H3K18ub and H3K23ub, respectively) (PubMed:29053958). Localized to the perinucleolar region (PubMed:24492612). .
- Nucleoplasm
- PubMed 12145218
- PubMed 24492612
- PubMed 29053958
- Tissue specificity (tau)
- 0.771992
- Expression inequality (Gini)
- 0.367915
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 83.96
- Testis
- 56.59
- Brain - Cerebellar Hemisphere
- 54.82
- Brain - Cerebellum
- 53.62
- Cells - Cultured fibroblasts
- 46.47
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes83.96
- Testis56.59
- Brain - Cerebellar Hemisphere54.82
- Brain - Cerebellum53.62
- Cells - Cultured fibroblasts46.47
- Cervix - Endocervix32.67
- Nerve - Tibial31.73
- Lung30.02
- Cervix - Ectocervix29.98
- Uterus29.18
- Spleen28.69
- Fallopian Tube28.64
- Small Intestine - Terminal Ileum24.83
- Vagina24.19
- Bladder23.45
- Breast - Mammary Tissue22.81
- Thyroid22.35
- Adipose - Subcutaneous22.29
- Ovary21.95
- Pituitary20.68
- Esophagus - Mucosa20.48
- Skin - Sun Exposed (Lower leg)20.3
- Skin - Not Sun Exposed (Suprapubic)20.1
- Artery - Coronary19.5
- Prostate18.77
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0010628
- GO:0010629
- GO:0044027
- GO:0141119
- GO:1900240
- GO:1904707
- GO:1905064
- GO:1905460
- GO:0000792
- GO:0005634
- GO:0005654
- GO:0005694
- GO:0005739
- GO:0003677
- GO:0003886
- GO:0005515
- GO:0009008
- GO:0140254
- GO:0140257
- GO:0140258
- GO:1990841
Related records
Trials (1,090)
- "InDACtion" vs "3+7" Induction in AML
- 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
- 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
- 5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates
- 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
- A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
- A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
- A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
- A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
- A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
- A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
- A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
- A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
- A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
- A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
- A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
- A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia
Drugs (2)
- Azacitidine DNA (cytosine-5)-methyltransferase 1 inhibitor
- Decitabine DNA (cytosine-5)-methyltransferase 1 inhibitor